Cardiovascular risk assessment with oxidised LDL measurement in postmenopausal women receiving intranasal estrogen replacement therapy

Gynecological Endocrinology

Volumn 27, Issue 8, 2011, Pages 551-557

  Kurdoglu, Mertihan ^a,b   Yildirim, Mulazim ^b   Kurdoglu, Zehra ^a,b   Erdem, Ahmet ^b   Erdem, Mehmet ^b   Bilgihan, Ayse ^b   Goktas, Bulent ^b  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

Author keywords

cardiovascular risk; hormone replacement therapy; intranasal estrogen; Oxidised LDL; postmenopausal woman; progesterone

Indexed keywords

APOLIPOPROTEIN B; ESTROGEN; HOMOCYSTEINE; LIPID; LIPOPROTEIN A; OXIDIZED LOW DENSITY LIPOPROTEIN; PROGESTERONE;

ARTICLE; BODY MASS; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN THERAPY; FEMALE; HUMAN; LIPID BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYSTERECTOMY; LIPOPROTEINS, LDL; MIDDLE AGED; OVARIECTOMY; PATIENT DROPOUTS; POSTMENOPAUSE; PROGESTERONE; RISK FACTORS; TURKEY;

EID: 79959997671     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.501879     Document Type: Article

References (34)

1. Wenger NK. Menopausal hormone therapy: currently no evidence for cardiac protection. Pediatr Blood Cancer 2005;44:625-629. (Pubitemid 40629212)
2. Williams JK, Suparto I. Hormone replacement therapy and cardiovascular disease: lessons from a monkey model of postmenopausal women. ILAR J 2004;45:139-146.
3. Ben-Chetrit A, Zacut D, Shimonovitz S. The effectiveness of estrogen replacement therapy to reduce ischemic heart disease - revaluation. Harefuah 2003;142:32-37, 78.
4. Sitruk-Ware RL. Hormone therapy and the cardiovascular system: the critical role of progestins. Climacteric 2003; 6(Suppl 3):21-28. (Pubitemid 38112890)
5. Ikenoue N, Wakatsuki A, Okatani Y. Small low-density lipoprotein particles in women with natural or surgically induced menopause. Obstet Gynecol 1999;93:566-570. (Pubitemid 29147077)
6. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992;93:189-199.
7. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-1921.
8. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2002;106:1771-1776.
9. Ratner S, Ofri D. Menopause and hormone replacement, Part 1: Evaluation and treatment. West J Med 2001;174:400-404.
10. Flegg HM. An investigation of the determination of serum cholesterol by an enzymatic method. Ann Clin Biochem 1973; 10:79-84.
11. Sachiko I. A new, direct method for measuring HDLcholesterol which does not produce any biased values. J Med Pharm Sci 1997;37:1385-1388.
12. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982;28:2077-2080. (Pubitemid 12034053)
13. Steinmetz J, Tarallo P, Fournier B, Caces E, Siest G. Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. Eur J Clin Chem Clin Biochem 1995;33:337-342.
14. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, Couderc R, Dati F, Rifai N, Sakurabayashi I, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000;46:1956-1967.
15. Mattsson LA, Christiansen C, Colau JC, Palacios S, Kenemans P, Bergeron C, Chevallier O, Von Holst T, Gangar K. Clinical equivalence of intranasal and oral 17b-estradiol for postmenopausal symptoms. Am J Obstet Gynecol 2000;182: 545-552. (Pubitemid 30207310)
16. Kiran H, Kiran G, Ekerbicer HC, Kilinc M. Effects of intranasal estradiol treatment on serum lipoprotein(a) and lipids in hysterectomized women. Gynecol Obstet Invest 2004;57:191-195. (Pubitemid 38608329)
17. Harma M, Kocyigit A, Yaltali T. Intranasal 17b-estradiol treatment and Vitamin B12, folate and homocysteine in menopause. Maturitas 2005;50:353-358. (Pubitemid 40365041)
18. Baksu B, Davas I, Agar E, Akyol A, Uluocak A. Do different delivery systems of estrogen therapy influence serum lipids differently in surgically menopausal women? J Obstet Gynaecol Res 2007;33:346-352. (Pubitemid 46934556)
19. Hemelaar M, Kenemans P, de Bie L, van de Weijer PH, van der Mooren MJ. Intranasal continuous combined 17 betaestradiol/ norethisterone therapy improves the lipid profile in healthy postmenopausal women. Fertil Steril 2006;85:979-988.
20. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS, Clarkson TB. Inhibition of coronary artery atherosclerosis by 17-b estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-1057.
21. Haarbo J, Leth-Espensen P, Stender S, Christiansen C. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J Clin Invest 1991;87:1274-1279.
22. Haarbo J, Svendsen OL, Christiansen C. Progestogens do not affect aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. Circ Res 1992;70:1198-1202.
23. Hanke H, Hanke S, Bruck B, Brehme U, Gugel N, Finking G, Muck AO, Schmahl FW, Hombach V, Haasis R. Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis 1996;121: 129-138. (Pubitemid 26074215)
24. Hanke H, Hanke S, Finking G, Muhic-Lohrer A, Muck AO, Schmahl FW, Haasis R, Hombach V. Different effects of estrogen and progesterone on experimental atherosclerosis in female versus male rabbits. Quantification of cellular proliferation by bromodeoxyuridine. Circulation 1996;94: 175-181. (Pubitemid 26240554)
25. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17: 217-221. (Pubitemid 27057346)
26. Adams MR, Williams JK, Kaplan JR. Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 1995;15:562-570.
27. Imthurn B, Rosselli M, Jaeger AW, Keller PJ, Dubey RK. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17b-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab 1997;82:388-394. (Pubitemid 27068598)
28. Zhu X, Bonet B, Knopp RH. Estradiol 17b inhibition of LDL oxidation and endothelial cell cytotoxicity is opposed by progestins to different degrees. Atherosclerosis 2000;148: 31-41.
29. Ahotupa M, Rauramo I, Vasankari TJ, Skouby SO, Hakonen T. Estrogen replacement therapy in combination with continuous intrauterine progestin administration reduces the amount of circulating oxidized LDL in postmenopausal women: dependence on the dose of progestin. Ann Med 2004;36:278-284. (Pubitemid 38789282)
30. Subakir SB, Abdul Madjid O, Sabariah S, Affandi B. Oxidative stress, vitamin E and progestin breakthrough bleeding. Hum Reprod 2000;15(Suppl 3):18-23.
31. McManus J, McEneny J, Young IS, Thompson W. The effect of various oestrogens and progestogens on the susceptibility of low density lipoproteins to oxidation in vitro. Maturitas 1996;25:125-131. (Pubitemid 26336677)
32. Castelo-Branco C, Coloma JL. The role of intranasal estradiol spray in the management of moderate to severe vasomotor symptoms in menopausal women. Gynecol Endocrinol 2010;26:23-29.
33. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712. (Pubitemid 38489892)
34. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. (Pubitemid 34761611)